{Reference Type}: Case Reports
{Title}: Polymyxin B-induced Bartter syndrome.
{Author}: Mohan Lal B;Musthafa Hafeesa N;Vikram NK;Ray A;
{Journal}: BMJ Case Rep
{Volume}: 17
{Issue}: 5
{Year}: 2024 May 3
暂无{DOI}: 10.1136/bcr-2023-255242
{Abstract}: Bartter syndrome is a genetic disorder characterised by chloride-unresponsive metabolic alkalosis, hypokalaemia, hypomagnesaemia and hypercalciuria. While it commonly presents antenatally or in early infancy, sometimes, drugs can induce a state similar to Bartter syndrome in any age group, called acquired Bartter syndrome. Polymyxins and aminoglycosides are the most commonly implicated drugs. Polymyxin B and polymyxin E (popularly known as colistin) are the two chemically similar polymyxins that are commonly used clinically. While colistin is frequently associated with nephrotoxicity, polymyxin B is generally considered less nephrotoxic. This difference is due to the way these two drugs are handled by the kidneys. In this case report, we discuss a middle-aged male who developed Bartter syndrome due to polymyxin B, which resolved on discontinuation of the drug, and re-appeared after its re-introduction later. This case exemplifies the nephrotoxicity caused by polymyxin B and the need for vigilance when using this drug.